Afresa New Drug Application
Links shared publicly online about this topic.
- 2,181total visits
Afresa New Drug Application
View full resource at drugs.com
Tags: Diabetes, Diabetes Medication, High Blood Sugar, Insulin, Type 2 Diabetes, Drug, Clinical Trial, Afresa
Most Recently Shared on March 18, 2009 at 8:29 pm By:
MannKind Submits NDA for Afresa for Treatment of Diabetes - http://tinyurl.com/cedvmu
FDA Advisory Committee to review Repligen's SecreFlo NDA on May 31
news-medical.net — “Repligen Corporation today announced that the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the Company's New Drug Application (NDA) for SecreFlo for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis.” View full resource at news-medical.net
Most Recently Shared on March 26, 2012 at 4:52 am By:
FDA Advisory Committee to review Repligen's SecreFlo NDA on May 31: Repligen Corporation today announced that th... http://t.co/ohY0Iubt
POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540 - Drugs.com MedNews
drugs.com — “New Drug Application Submission Anticipated in Q3 2012 Detailed Results to be Submitted for Journal Publication and Presentation at a Future Scientific Meeting” View full resource at drugs.com
Most Recently Shared on March 22, 2012 at 1:07 pm By:
Drugs and Devices OW OW Health
POZEN Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of PA32540: New Drug Applicatio... http://t.co/a45T1YSl #drug
Analysis reveals most common Cancer Drugs Fund applications : Cancer Research UK
info.cancerresearchuk.org — “New figures have revealed which drugs attracted the most applications to England's £200m Cancer Drugs Fund.” View full resource at info.cancerresearchuk.org
Most Recently Shared on March 21, 2012 at 1:33 pm By:
Cancer Research UK Health Organization
News: Analysis reveals most common Cancer Drugs Fund applications http://t.co/BSeQvHyF
Abbott files suit against Watson over generic NIASPAN
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Niacin Extended-release Tablets, 500 mg and 1000 mg. Watson's ANDA products are generic versions of Abbott Laboratories' NIASPAN.” View full resource at news-medical.net
Most Recently Shared on March 19, 2012 at 2:01 pm By:
Abbott files suit against Watson over generic NIASPAN: Watson Pharmaceuticals, Inc. today confirmed that its sub... http://t.co/pk3MiGAR
PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine
news-medical.net — “PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.” View full resource at news-medical.net
Most Recently Shared on March 19, 2012 at 1:12 pm By:
Bird Flu News: PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine: PaxVax Corporation, develop... http://t.co/vN7utz5a
FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials.” View full resource at finance.yahoo.com
Most Recently Shared on March 19, 2012 at 1:03 pm By:
FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine: PaxVax Corporation, developer of innovative and s... http://t.co/S88mL9v2
NIDA seeks SBIR/STTR apps on Spice, bath salts | Terra Sigillata
cenblog.org — “C&EN senior business editor Melody Baumgartner dropped me a note yesterday about a new request for applications from NIH’s National Institute on Drug Abuse (NIDA) for small business grants. Read the text below but here’s what I find interesting as a pharmacologist who plays well with chemists: the call for applications is not for analytical [...]” View full resource at cenblog.org
Most Recently Shared on March 15, 2012 at 8:33 pm By:
David J Kroll Science Enthusiast
NIDA solicits SBIR/STTR proposals on pharmacodynamic, not analytical chem, detection of Spice, bath salts http://t.co/kZGHGGL8 #FakeWeed
Biodel to Provide Update on Stabilized Glucagon Program at ROTH Conference Today -- DANBURY, Conn., March 14, 2012 /PRNewswire/ --
prnewswire.com — “Biodel to Provide Update on Stabilized Glucagon Program at ROTH Conference Today. New Drug Application for Stabilized Liquid Glucagon submission projected in late 2013 or early 2014.” View full resource at prnewswire.com
Most Recently Shared on March 14, 2012 at 8:37 pm By:
Scott Strumello Patient Expert
Biodel to Provide Update on Stabilized Glucagon Program at ROTH Conference Today (March 14, 2012) http://t.co/EXjgcqUM via @PRNewswire
Nanotube technology leading to new era of fast, lower-cost medical diagnostics
sciencedaily.com — “Researchers have tapped into the extraordinary power of carbon "nanotubes" to increase the speed of biological sensors, a technology that might one day allow a doctor to routinely perform lab tests in minutes, speeding diagnosis and treatment while reducing costs. The new findings have almost tripled the speed of prototype nano-biosensors, and should find applications not only in medicine but in toxicology, environmental monitoring, new drug development and other fields.” View full resource at sciencedaily.com
Most Recently Shared on March 13, 2012 at 12:14 pm By:
Nanotube #technology leading to new era of fast, lower-cost #medical #diagnostics: #path #lab #pharm http://t.co/fK66ggaM via @AddThis
Nanotube technology leading to new era of fast, lower-cost medical diagnostics
sciencedaily.com — “Researchers have tapped into the extraordinary power of carbon "nanotubes" to increase the speed of biological sensors, a technology that might one day allow a doctor to routinely perform lab tests in minutes, speeding diagnosis and treatment while reducing costs. The new findings have almost tripled the speed of prototype nano-biosensors, and should find applications not only in medicine but in toxicology, environmental monitoring, new drug development and other fields.” View full resource at sciencedaily.com
Most Recently Shared on March 12, 2012 at 9:38 pm By:
Nanotube technology leading to new era of fast, lower-cost medical diagnostics: Researchers have tapped into the... http://t.co/giAa7YcQ
Nanotube technology leading to new era of fast, lower-cost medical diagnostics
eurekalert.org — “Researchers have tapped into the extraordinary power of carbon "nanotubes" to increase the speed of biological sensors, a technology that might one day allow a doctor to routinely perform lab tests in minutes, speeding diagnosis and treatment while reducing costs. The new findings have almost tripled the speed of prototype nano-biosensors, and should find applications not only in medicine but in toxicology, environmental monitoring, new drug development and other fields.” View full resource at eurekalert.org
Most Recently Shared on March 9, 2012 at 9:26 pm By:
Nanotube technology leading to new era of fast, lower-cost medical diagnostics: ( Oregon State University ) Rese... http://t.co/DcY9Nr1G
NDA Submitted for Vibex for Keratoconus and Corneal Ectasia - MPR
empr.com — “Avedro announced that it has submitted a New Drug Application (NDA) to the FDA for VibeX (riboflavin ophthalmic solution) /KXL System for the treatment of keratoconus and corneal ectasia following refractive surgery.” View full resource at empr.com
Most Recently Shared on March 8, 2012 at 10:01 pm By:
NDA Submitted for Vibex for Keratoconus and Corneal Ectasia http://t.co/0Y9WFwQN #ocular #ophthalmic
Smart, self-healing hydrogels open new possibilities in medicine, engineering
physorg.com — “University of California, San Diego bioengineers have developed a self-healing hydrogel that binds in seconds, as easily as Velcro, and forms a bond strong enough to withstand repeated stretching. The material has numerous potential applications, including medical sutures, targeted drug delivery, industrial ...” View full resource at physorg.com
Most Recently Shared on March 6, 2012 at 2:38 am By:
HealthFuturesDigest Health Organization
Materials: Self-healing acid-sensitive hydrogel could be great for suturing stomach lesions, among other medical uses. http://t.co/g2GDPtpV
Decision on Apixaban (Eliquis) Pushed Back By Three Months - Forbes
forbes.com — “Confirming earlier speculation by a Wall Street analyst, Pfizer and Bristol-Myers Squibb announced on Wednesday evening that the FDA had extended by three months the action date for the new drug application (NDA) for the highly anticipated oral anticoagulant Eliquis (apixaban). The application is for their important indication of stroke [...]” View full resource at forbes.com
Most Recently Shared on March 1, 2012 at 11:54 am By:
Maybe a Pradaxa side effect, analyst says RT @blogaceutics: #FDA Decision on Eliquis Pushed Back By Three Months—Forbes http://t.co/pesyJ6FF
NDA Accepted for Tafamidis Meglumine for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) - MPR
empr.com — “Pfizer Inc. announced that the FDA has accepted its New Drug Application (NDA) for tafamidis meglumine for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).” View full resource at empr.com
Most Recently Shared on February 15, 2012 at 3:55 pm By:
NDA Accepted for Tafamidis Meglumine for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) http://t.co/hltLvmxI #neurodegenerative
Advertisement
